immune cells

Aubagio shifts immune cell balance in RRMS, study reveals

Aubagio (teriflunomide), an approved therapy for relapsing forms of multiple sclerosis (MS), works by shifting the balance between activated subsets of nerve-damaging immune cells to those with immunosuppressive traits, a new study reveals. Further studies to understand how changes in immune cell subsets drive Aubagioā€™s clinical effectiveness will…

New study data may help explain EBV and MS link

When the immune system launches an attack to fight off infection with the Epstein-Barr virus, immune cells can accidentally end up targeting a protein called CRYAB that’s normally expressed by healthy myelin-making cells in the brain, a study found. The findings provide further evidence that molecular similarities between distinct…

Researchers uncover key biological pathway for MS

Interleukin-3 (IL-3), an inflammatory signaling protein, seems to coordinate the recruitment of immune cells from the blood into the brain, leading to worsening inflammation and symptoms related to multiple sclerosis (MS), a study revealed. Targeting IL-3-mediated communication may be an effective therapeutic strategy for MS and other brain disorders,…

Blood Stem Cell Transplant May Help Immune System Longer

Treatment with an autologous hematopoietic stem cell transplant (aHSCT) seems to reboot the immune system in multiple sclerosis (MS) patients for at least three years, a small study found. The study, ā€œSustained immunotolerance in multiple sclerosis after stem cell transplant,ā€ was published in Annals of Clinical and…

Researchers Identify Subset of Immune Cells Driving MS

A new subset of type 3 innate lymphoid cells (ILC3s) ā€” a type of immune cell known mostly for its anti-inflammatory and immunosuppressive effects in the gut ā€” infiltrates the brain and promotes the abnormal immune attacks that drive multiple sclerosisĀ (MS), according to a study in a mouse model…

#AANAM ā€“ Exploring Mavenclad’s Effects on Immune Cells

Editorā€™s note: TheĀ Multiple Sclerosis News TodayĀ team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, held April 17ā€“22. GoĀ hereĀ to read stories from the conference. After starting treatment with the multiple sclerosis (MS) therapy Mavenclad (cladribine), some types of immune cells are more affected…

#MSVirtual2020 – Masitinib Delays Disability Progression in PPMS, Non-active SPMS

AB Scienceā€™s lead candidate masitinibĀ safely and effectively delays disability progression in people withĀ primary progressive multiple sclerosisĀ (PPMS) and non-activeĀ secondary progressive MSĀ (SPMS), according to top-line data from a clinical trial. The therapy was found to significantly lower the risk of first and confirmed (three-month) disability progression, and to reduce…